<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One of the main challenges in radiation <z:hpo ids='HP_0002664'>oncology</z:hpo> is to overcome the resistance of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells against treatment by molecular targeted approaches </plain></SENT>
<SENT sid="1" pm="."><plain>Among the most promising targets is the inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> protein survivin, known to be associated with increased <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> and therapy resistance </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was the development of a human serum albumin-based nanoparticulate carrier system for plasmid-mediated <z:chebi fb="40" ids="33697">RNA</z:chebi> interference (miRNA) and the investigation of its in vitro efficacy on survivin knockdown and cellular toxicity in SW480 <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>The results demonstrate a robust nanoparticulate system of a size around 220 nm with a plasmid incorporation efficacy of about 90% </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, treatment of <z:mp ids='MP_0002038'>carcinoma</z:mp> cells with survivin-miRNA nanoparticles resulted in reduction of survivin expression by 50% and increased cytotoxicity if combined with ionising irradiation </plain></SENT>
<SENT sid="5" pm="."><plain>These nanoparticles comprise a promising option to enhance the response of <z:mp ids='MP_0002038'>carcinoma</z:mp> cells to therapy with ionising irradiation </plain></SENT>
</text></document>